Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 23, 2019 07:30 ET | Source: OpGen, Inc.

OpGen Provides Update on Curetis Group Business Receiving U.S. FDA 510(k) Clearance of its Unyvero LRT for BAL Specimens

- Broad Unyvero LRT BAL panel also includes atypical pathogens such as Pneumocystis jirovecii - Clearance expected to substantially increase total addressable market for Unyvero System in the U.S. -...
December 02, 2019 07:30 ET | Source: OpGen, Inc.

OpGen Provides Curetis Group Business Update and Announces Completion of Key Milestones in Planned Business Combination

Curetis Expects Near-Term U.S. FDA Decision on 510(k) Clearance of Unyvero LRT for BAL Specimens European Investment Bank approves business combination transaction ...
November 19, 2019 07:30 ET | Source: OpGen, Inc.

OpGen Products in Development to Address “Urgent Threat” Pathogens Highlighted in New CDC Report on Antibiotic Resistance Threats

GAITHERSBURG, Md., Nov. 19, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that the Center for Disease Control (CDC) has released updated data increasing the number of deaths in...
November 06, 2019 16:05 ET | Source: OpGen, Inc.

OpGen Reports Third Quarter 2019 Financial Results and Provides Business Update

22% Revenue Increase Year-to-Date Update on Announced Agreement to Combine Business with Curetis Conference call to be held at 4:30 p.m. Eastern Time today GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE...
November 04, 2019 07:30 ET | Source: OpGen, Inc.

OpGen Provides Update on Curetis Group Company Ares Genetics Business

Ares Genetics Launches AI-powered Molecular Antibiotic Susceptibility Test (AST)Orders for more than 1,000 molecular AST tests offered under the brand name ARESupa – Universal Pathogenome AssayTotal...
October 29, 2019 16:05 ET | Source: OpGen, Inc.

OpGen Announces Date of Third Quarter 2019 Financial Results Conference Call

GAITHERSBURG, Md., Oct. 29, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) announced today that the Company will report its third quarter 2019 financial results after the close of the U.S....
October 28, 2019 11:51 ET | Source: OpGen, Inc.

OpGen Announces Closing of $9.4 Million Underwritten Public Offering

GAITHERSBURG, Md., Oct. 28, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN) today announced the closing of its previously announced underwritten public offering of 2,590,170 units at $2.00 per...
October 23, 2019 23:16 ET | Source: OpGen, Inc.

OpGen Announces Pricing of $9.4 Million Underwritten Offering

GAITHERSBURG, Md., Oct. 23, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN) today announced the pricing of an underwritten offering of an aggregate of 4,700,000 units at an effective price of...
October 23, 2019 07:30 ET | Source: OpGen, Inc.

U.S. Patent Allowed Covering Acuitas Lighthouse® Software

GAITHERSBURG, Md., Oct. 23, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that the United States Patent and Trademark Office (the “USPTO”) has allowed a key OpGen patent...
October 07, 2019 07:30 ET | Source: OpGen, Inc.

OpGen Presents Preliminary Acuitas® AMR Gene Panel Data for Detecting Urinary Tract Infections

GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) today announced the presentation of preliminary data at IDWeek 2019 for the Company’s Acuitas® AMR Gene Panel and...